Clinical characteristics and natural history of patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations treated with erlotinib or gefitinib.

被引：0
|
作者：
Riely, GJ [1 ]
Miller, VA [1 ]
Pao, W [1 ]
Zakowski, M [1 ]
Ladanyi, M [1 ]
Heelan, RT [1 ]
Kris, MG [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：641S / 641S
页数：1
相关论文
共 50 条
  • [1] Intercalated chemotherapy and erlotinib for non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations
    Zwitter, Matjaz
    Rajer, Mirjana
    Stanic, Karmen
    Vrankar, Martina
    Doma, Andrej
    Cuderman, Anka
    Grmek, Marko
    Kern, Izidor
    Kovac, Viljem
    [J]. CANCER BIOLOGY & THERAPY, 2016, 17 (08) : 833 - 839
  • [2] Inherited EGFR variants and survival in patients with non-small cell lung cancer (NSCLC) treated with gefitinib.
    Gregorc, V
    Hidalgo, M
    Spreafico, A
    Aondio, G
    Cusatis, G
    Marsh, S
    Steinberg, SM
    Ludovini, V
    Villa, E
    Sparreboom, A
    Baker, SD
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9079S - 9079S
  • [3] Mutations in the epidermal growth factor receptor (EGFR): Retro-and prospective observations in non-small cell lung cancer (NSCLC) patients (pts) treated with gefitinib
    Nederlof, R
    Boerrigter, L
    Van 't Veer, L
    Baas, P
    van Zandwijk, N
    [J]. LUNG CANCER, 2005, 49 : S111 - S111
  • [4] ERLOTINIB AFTER FAILURE OF GEFITINIB THERAPY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) WITH OR WITHOUT EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION
    Saito, Hiroshi
    Kimura, Tomoki
    Abe, Takashi
    Kondo, Masashi
    Ogasawara, Tomohiko
    Tanikawa, Yoshimasa
    Yokoyama, Toshihiko
    Kojima, Eiji
    Yamamoto, Masashi
    Suzuki, Ryujiro
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1210 - S1211
  • [5] Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib
    Riely, GJ
    Pao, W
    Pham, DK
    Li, AR
    Rizvi, N
    Venkatraman, ES
    Zakowski, MF
    Kris, MG
    Ladanyi, M
    Miller, VA
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (03) : 839 - 844
  • [6] Mutations of the epidermal growth factor receptor (EGFR) gene in non-small cell lung cancer (NSCLC).
    Sonobe, M
    Katakura, H
    Adachi, T
    Wada, H
    Tanaka, F
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 637S - 637S
  • [7] Potential clinical prognostic factors in non-small cell lung cancer (NSCLC) patients treated with gefitinib.
    Villaflor, VM
    Polowy, CR
    Coon, JS
    Leslie, WT
    Lukic, I
    Kanevsky, G
    Gale, M
    Stewart, I
    Bonomi, P
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 638S - 638S
  • [8] Molecular characteristics of non-small cell lung cancer (NSCLC) patients sensitive to gefitinib.
    Pao, W
    Zakowski, M
    Cordon-Cardo, C
    Ben-Porat, L
    Kris, MG
    Miller, VA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 623S - 623S
  • [9] Clinical Features of Patients with Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations in Brunei
    Lu, S. K.
    Leong, C. H.
    Diah, S. Binti Hj Mohd
    Patnaik, R.
    Sukumaran, B.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2207 - S2207
  • [10] Epidermal growth factor receptor mutations in Greek gefitinib-treated non-small-cell lung cancer (NSCLC) patients
    Voutsina, A
    Pallis, AG
    Souglakos, J
    Koutsopoulos, A
    Kalykaki, A
    Trypaki, M
    Mavroudis, D
    Georgoulias, V
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 42 - 42
12345